Durvalumab FDA approval date

The FDA approved Durvalumab (Imfinzi) on 1 May 2017.

FDA approval date
1 May 2017

Drug identity checked against registry records

Also recorded as Imfinzi

Included trials

PDUFA dates and FDA decisions

Date as reportedDrug / companyEventConditionEvidence
2017-05-01DayDurvalumabFDA original application approvalFDA approval decisionNot specifiedOpen original source
Read source excerpt

{"application_number": "BLA761069", "applicant_as_listed_by_fda": "ASTRAZENECA UK LTD", "brand_names": ["IMFINZI"], "active_ingredients": ["DURVALUMAB"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20170501", "matched_on": "drug name equals FDA sole active ingredient"}

First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026